Reduced cerebrospinal fluid estradiol levels are associated with increased β-amyloid levels in female patients with Alzheimer's disease

被引：63
作者：
Schönknecht, P
Pantel, J
Klinga, K
Jensen, M
Hartmann, T
Salbach, B
Schröder, J
机构：
[1] Univ Heidelberg, Dept Psychiat, Serv Geriat Psychiat, D-69115 Heidelberg, Germany
[2] Univ Heidelberg, Dept Endocrinol Gynecol, D-69115 Heidelberg, Germany
[3] KFC Novum, Div Geriatr Med, Neurotec Dept, Karolinska Inst, Huddinge, Sweden
[4] Univ Heidelberg, Ctr Mol Biol Heidelburg ZMBH, D-69115 Heidelberg, Germany
来源：
NEUROSCIENCE LETTERS | 2001年 / 307卷 / 02期
关键词：
Alzheimer's disease; 17; beta-estradiol; estrogen replacement therapy; beta-amyloid;
D O I：
10.1016/S0304-3940(01)01896-1
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Recent in-vitro studies indicate that estrogens such as 17 beta -estradiol (E-2) may decrease the production of beta -amyioid 1-2 (A beta 42), a peptide central for the formation of senile plaques in Alzheimer's disease (AD). To test this hypothesis in a clinical study, cerebrospinal fluid levels of E-2 were compared between 30 female AD patients and 11 female patients with non-dementing diseases such as major depression and investigated with respect to beta -amyloid 1-40 and A beta 42 levels. E-2 levels were significantly (P < 0.05) lower in the AD group than in controls; within the AD group E-2 levels were inversely correlated with A<beta>42 concentrations (r= -0.36, P = 0.05). This is the first clinical study providing evidence for an influence of E-2 on A beta 42 metabolism in vivo. This observation corresponds to the putative beneficial effects of estrogen replacement therapy on the development and course of AD. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码：122 / 124
页数：3
相关论文
共 20 条
[1]   Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study [J].
Asthana, S ;
Craft, S ;
Baker, LD ;
Raskind, MA ;
Birnbaum, RS ;
Lofgreen, CP ;
Veith, RC ;
Plymate, SR .
PSYCHONEUROENDOCRINOLOGY, 1999, 24 (06) :657-677
[2]   Neuroprotection against oxidative stress by estrogens: Structure-activity relationship [J].
Behl, C ;
Skutella, T ;
Lezoualch, F ;
Post, A ;
Widmann, M ;
Newton, CJ ;
Holsboer, F .
MOLECULAR PHARMACOLOGY, 1997, 51 (04) :535-541
[3]  
Birge SJ, 1997, Am J Med, V103, P36
[4]   MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN [J].
FOLSTEIN, MF ;
FOLSTEIN, SE ;
MCHUGH, PR .
JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) :189-198
[5]   CELLULAR PROCESSING OF BETA-AMYLOID PRECURSOR PROTEIN AND THE GENESIS OF AMYLOID BETA-PEPTIDE [J].
HAASS, C ;
SELKOE, DJ .
CELL, 1993, 75 (06) :1039-1042
[6]   Estrogen for Alzheimer's disease in women - Randomized, double-blind, placebo-controlled trial [J].
Henderson, VW ;
Paganini-Hill, A ;
Miller, BL ;
Elble, RJ ;
Reyes, PF ;
Shoupe, D ;
McCleary, CA ;
Klein, RA ;
Hake, AM ;
Farlow, MR .
NEUROLOGY, 2000, 54 (02) :295-301
[7]  
JAFFE AB, 1994, J BIOL CHEM, V269, P13065
[8]  
Jensen M, 1999, ANN NEUROL, V45, P504, DOI 10.1002/1531-8249(199904)45:4<504::AID-ANA12>3.0.CO
[9]  
2-9
[10]   A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging [J].
Kawas, C ;
Resnick, S ;
Morrison, A ;
Brookmeyer, R ;
Corrada, M ;
Zonderman, A ;
Bacal, C ;
Lingle, DD ;
Metter, E .
NEUROLOGY, 1997, 48 (06) :1517-1521
12